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Abstract
Background: The aim was to evaluate the effects of 
glutamine on tumor regression and histological damage 
in patients with rectal patients following chemoradiothe-
rapy previous to surgery.
Material and methods: Ten patients with rectal cancer 
surgically removed after chemoradiotherapy were inclu-
ded, a subgroup of a randomized trial that compared glu-
tamine and placebo in the prevention of acute radiation 
enteritis. Samples of neoplasm and healthy tissue were 
evaluated by an expert pathologist searching for signs of 
tumor regression, muciphages, and signs of radiation-in-
duced damage.
Results: There were no differences in the grade of 
tumor regression with either glutamine or placebo. All 
patients who received glutamine presented muciphages, 
compared with 28.6% of the placebo group (p = 0.038). 
Histological damage was similar in patients receiving 
glutamine or placebo, and between those with radiation 
enteritis or without toxicity. 
Conclusion: Glutamine did not exert a protective 
effect over chemoradiotherapy in rectal cancer or heal-
thy rectal tissue.
(Nutr Hosp. 2015;31:1689-1692)
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Resumen
Introducción: El objetivo fue evaluar los efectos de la 
administración de glutamina sobre la regresión tumoral 
y sobre el tejido sano en pacientes con cáncer rectal que 
recibieron quimiorradioterapia.
Material y métodos: Se incluyó 10 pacientes con cáncer 
rectal operado después de quimiorradioterapia, un subgru-
po de un ensayo clínico que comparó glutamina con place-
bo en la prevención de enteritis aguda. Un patólogo experto 
analizó las muestras de tumor y tejido sano, buscando da-
tos de regresión tumoral, mucífagos y daño por radiación. 
Resultados: No hubo diferencias entre placebo y glu-
tamina en el grado de regresión tumoral. Todos los pa-
cientes con glutamina presentaron mucífagos, frente al 
28,6% con placebo (p = 0,038). El daño sobre tejido sano 
fue similar en los pacientes con glutamina y placebo, y 
entre aquellos con y sin enteritis. 
Conclusión: La glutamina no ejerce un efecto protec-
tor frente a la quimiorradioterapia sobre el tumor o el 
tejido rectal sano.
(Nutr Hosp. 2015;31:1689-1692)
DOI:10.3305/nh.2015.31.4.8521
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Introduction
Glutamine is an amino acid with antioxidant and 
trophic properties that has been widely used as an 
immunonutrient with the purpose of modifying the 
progression of several diseases. Regarding the toxici-
ty caused by radiotherapy, a previous trial from our 
group showed an increase in the number of cases of 
acute and chronic diarrhea in patients receiving glu-
tamine during radiotherapy, compared with placebo1,2. 
The aim of the current study was to assess the effects 
of glutamine on tissue damage and tumor regression in 
rectal cancer patients treated with chemoradiotherapy.
Subjects and methods
The methodology followed in this trial has been pre-
viously reported1. Briefly, a randomized, controlled, 
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double-blind study was designed to compare the effec-
tiveness of glutamine versus placebo in the prevention 
of radiation enteritis. The treatment group received 30 
g/day of oral glutamine and the placebo group received 
30 g/day of whole casein, from 3 days before starting 
radiotherapy until the completion of antitumor treat-
ment. The study was evaluated by the local Research 
Ethics Committee, which confirmed that the study fo-
llowed the Declaration of Helsinki, and it was registe-
red in Clinical Trials (www.clinicaltrials.gov) with the 
number NCT00828399. Written informed consent was 
obtained from every patient.
The current analysis included a subgroup of patients 
with rectal cancer in which surgery was indicated after 
the completion of chemoradiotherapy. The sample ob-
tained in the operating room was processed according 
the standard procedure of the center, and analyzed 
by a pathologist experienced in colorectal tumors. A 
classification of rectal cancer regression after chemo-
radiotherapy has been developed by Ryan et al, after 
previous work by Mandard et al3,4. The grades of re-
gression described by Ryan include: grade 1, complete 
or almost complete regression (no viable or isolated 
tumor cells); grade 2, partial response (residual tumor 
smaller than fibrosis); grade 3, no response (significant 
fibrosis exceeded by tumor or residual tumor without 
extensive fibrosis). In our center, a modified version 
of Ryan’s grades is routinely used: grade 0 (complete 
response), grade 1 (moderate response), grade 2 (mi-
nimum response), and grade 3 (no response to treat-
ment). The following histological changes associated 
with radiotherapy were searched in normal rectal tis-
sue: lymphoplasmacytic or eosinophilic infiltration of 
the lamina propria, eosinophilic abscesses in crypts, 
edema or fibrosis of the lamina propria, fibrosis of the 
submucosa, thickening of the arteries of submucosa, 
alteration of architecture, and the presence of muci-
phages5,6,7.
The normal distribution of quantitative variables 
was examined by the Shapiro-Wilk test. Those mat-
ching a normal distribution were summarized as the 
mean and standard deviation (SD) and compared 
with paired Student’s t-test. Categorical variables 
were summarized as percentages and compared with 
the c2 test.
Results
The samples of 10 patients could be examined af-
ter surgery, three of them had received glutamine and 
seven placebo. The mean age was 72.3 (1.9) years, 
70.0% were males, the median dose of radiotherapy 
received was 45.0 Gy (interquartile range = 5.4), and 
30.0% developed acute radiation enteritis. There were 
no significant differences between the intervention 
groups in these characteristics. Tumor regression was 
similar in both groups, and in all patients some degree 
of response to treatment was observed (Table I). No 
significant differences were found between those who 
developed acute enteritis and those without toxicity: 
grade 0 (0.0% vs.16.7%), grade 1 (25.0% vs. 33.3%), 
and grade 2 (75.0% vs. 50.0%) (p = 0.615).
Histological changes in the normal rectum are sum-
marized in tables II and III. Some changes were not 
observed in the studied samples, like eosinophilic in-
filtration or edema of the lamina propria. 
Table I 
Comparison of the grade of tumor regression after 
preoperative chemoradiotherapy
Grade of regression
Glutamine
n (%)
Placebo
n (%)
p
Grade 0 
Complete regression 0 (0.0) 1 (14.3)
0.788
Grade 1
Moderate regression 1 (33.3) 2 (28.6)
Grade 2
Minimal regression 2 (66.7) 4 (57.1)
Grade 3 
No regression 0 (0.0) 0 (0.0)
Table II 
Comparison of histological changes in the rectum after preoperative chemoradiotherapy according to treatment
Grade of regression
Glutamine
n (%)
Placebo
n (%)
p
Lymphoplasmacytic infiltration of lamina propria 3 (100.0) 7 (100.0) 1.000
Eosinophilic infiltration of lamina propria 3 (100.0) 7 (100.0) 1.000
Eosinophilic abscesses in crypts 0 (0.0) 3 (42.9) 0.175
Edema of submucosa 0 (0.0) 5 (71.4) 0.038
Fibrosis of submucosa 2 (66.7) 3 (42.9) 0.490
Fibrosis of intima media of the arteries of submucosa 2 (66.7) 2 (28.6) 0.260
Alteration of architecture 0 (0.0) 1 (14.3) 0.490
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All the patients who received glutamine presented 
muciphages, but only 28.6% of the placebo group did 
(p = 0.038). These cells were found in 57.1% of pa-
tients with acute radiation enteritis and in 33.3% of 
those without intestinal toxicity (p = 0.490). 
Discussion
There are scarce opportunities to evaluate the effects 
of immunonutrients on human tissues due to the ethi-
cal issues related to the invasive procedures needed to 
obtain the samples. This study, in which rectal tumor 
and some normal tissue were surgically removed af-
ter chemoradiotherapy following the current guideli-
nes, offers the opportunity to describe the histological 
effects of glutamine. Although limited by the few pa-
tients included in this study, some observations could 
be highlighted. 
First, there were no differences in the efficacy of 
chemoradiotherapy in the two groups. This result 
may add some evidence against the potential trophic 
or protective role of glutamine on neoplastic cells, an 
adverse effect described in animals but with incon-
sistent data in humans8. In addition, a similar evo-
lution of tumoral markers had been observed in the 
patients recruited in this trial who received glutamine 
and those who received placebo, and the frequency 
of the different grades of regression was similar to 
that described by Ryan1,3. Some in vitro studies have 
found that the administration of glutamine does not 
inhibit the cytotoxic effects of chemoradiotherapy, 
and could even enhance them9.
Second, the presence of muciphages was signi-
ficantly more frequent in patients who received 
glutamine. These cells are mucosal macrophages 
containing mucin, which is obtained from the pha-
gocytosis of damaged crypts4,10. Although they can 
be found in almost 50% of rectal biopsies of healthy 
people, muciphages have been related to intestinal 
diseases and the repair of mucosal damage11,12,13. 
This finding may corroborate the link between the 
administration of oral glutamine and the develop-
ment of acute radiation enteritis that has been pre-
viously presented1.
Third, pathological findings in the normal rectum 
after the administration of chemoradiotherapy were 
unspecific and may be poorly related to the symptoms 
of enteritis. The only significant difference between 
glutamine and placebo was the presence of edema in 
the submucosa, and there were no differences between 
patients who developed intestinal toxicity and those 
with diarrhea.
In conclusion, and with all the caution that the limi-
ted number of patients imposes, these results may su-
pport that glutamine does not exert a protective effect 
on the normal rectum or rectal carcinoma. 
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